Fibromyalgia and cannabis: what evidence says

Fibromyalgia affects about 2 to 4% of the world's population with a higher prevalence among women. It is characterized by widespread musculoskeletal pain, persistent tiredness, sleep problems and cognitive dysfunction (what many patients call 'fibronifog'). It's a complex condition, misunderstood for decades, and frustrically difficult to deal with.

Medical cannabis has been an important option for patients who have been unable to respond to conventional treatment in recent years. What does the evidence really say? Let's try and look at him with clinical honesty and with no promise and no discard.

The endocannabinoid system and fibromyalgia

Our body produces its own cannabinoids, known as endocannabinoids, that act on CB1 and CB2 receptors distributed by the nerve and immune system. The system regulates functions such as pain, sleep, appetite, inflammation and mood.

A hypothesis studied for more than a decade, popularized by researcher Ethan Russo, is that of 'endocannabinoid clinical deficiency'. He suggests that some conditions such as fibromyalgia, chronic migraine and irritable bowel syndrome may be associated with poor regulation of this system. That's a reasonable and plausible assumption, but still inconclusive.

What suggests clinical evidence

Studies about fibromyalgia and cannabinoids evaluate different products and are generally small or heterogeneous. Some observed signs, which have yet to allow a general recommendation, include:

• Signs of pain reduction in some small studies with products containing THC.
• Changes to sleep or quality of life in some observational studies and studies.
• Results that cannot be moved automatically between THC, CBD, balanced formulations or non-standardised products.
• Retirement and clinical response between people.

A systematic review of 2023 described as low the quality of evidence that supports a shortterm pain reduction. Furthermore, a randomized trial published in 2025 did not support the use of oral CBD of 50 mg daily as an analgesic supplement. These results remember that CBD does not amount to THC and that there is no single conclusion for all cannabinoids.

What we don't know yet

Research has several important gaps that we should not hide:

• No standardized dose exists: each patient responds differently and titration is individual.
• Long-term information about tolerance, sustained cognitive effects and safety in 65 and older remains missing.
• There are few direct comparative studies with conventional frontline treatments.
• The variability between products (concentrations of cannabinoids, terpenes and administration) makes it difficult to extrapolate results from one study to another.

Security considerations

Medical cannabis isn't risk free and not all patients are candidates. Among the most common considerations:

• It can interact with medicines metabolized by the CYP450 system, including some anticoagulants and antiepileptics.
• It's not recommended for patients with a personal or family history of psychosis, psychotic disorders or serious addiction.
• It should be avoided during pregnancy and lactation.
• Some patients may have adverse events such as sedation, tachycardia, mouth dryness, cognitive impairment or paradoxical anxiety.

That's why we insisted: the decision to start medical cannabis should be made with a doctor who knows your clinical history, your current medicines and your background. It's not an "offmarket" treatment or an "inoculated natural remedy."

How to discuss this with your doctor

If you consider that medical cannabis could help with your fibromyalgia, some useful suggestions for consultation:

1. 1It carries a daily of symptoms: pain intensity, sleep quality, tiredness, mood. It's the best tool to objectively evaluate your response.
2. 2It detains all the treatments you have been trying, including doses and reasons why you suspended them.
3. 3It emits all current medicines, supplements and herbal products.
4. 4It raises concrete questions: what formulation (THC / CBD), what path (oral, inhaled), what specific therapeutic goal and how the response will be evaluated.